Table 3 Patients with symptomatic intracranial haemorrhage.

Patient no, sex, age (years)	NIHSS score	Occlusion site	IAT				Symptomatic intracranial haemorrhage			mRS‡
			Delay* (min)	Duration (min)	Dose†	TIMI grade	Delay (h)	Inside the infarct	Localisation
1, M, 57	19	CTO, incl ACA, PCA	210	105	1.25	1	1	Yes	Lobar, BG, IVH	6
2, F, 75	19	CTO, incl PCA	300	60	1	1	14	Yes	Lobar, IVH	6
3, M, 70	14	CTO	330	60	1	2	10	Yes	BG, IVH, SAH	6
4, F, 49	12	M1+LS	360	60	1	2	7	Yes	Lobar, BG, IVH	4
5, M, 67	19	M1+LS	300	60	1	2	<24	Yes	Lobar, BG, IVH, SAH	5
6, F, 68	21	M1+LS	180	60	1	1	4	Yes	Lobar, BG, IVH	6
7, F, 36	13	M1+LS	215	60	1	0	48–72	Yes	BG	3
8, M, 69	19	M1+LS	270	60	1	1	<24	Yes	Lobar, BG, IVH	6
9, M, 60	12	M1	230	60	1	2	48–72	Yes	Lobar	2
10, F, 71	11	M2	180	65	1	1	16	Yes	Lobar, BG, IVH	3
11, M, 73	12	M2	255	50	1	1	<24	Yes	Lobar, IVH	6
12, F, 70	12	M2	20	60	0.75	2	5	No	Lobar, IVH, SDH	4
13, M, 74	18	M2	240	50	1	1	7	Yes	Lobar	6
14, F, 43	35	BA	385	60	1	1	<24	Yes	Pons, IVH	6

ACA, anterior cerebral artery; BA, basilar artery; BG, basal ganglia; CTO, carotid T occlusion; F, female; IVH, intraventricular hyperdensity; LS, lenticulostriate arteries; M, male; M1 and M2, segments of middle cerebral artery; mRS, modified Rankin Score; PCA, posterior cerebral artery; SAH, subarachnoidal haemorrhage; SDH, subdural haemorrhage.

*Time interval from symptom onset to start of IAT.

†×10⁶ U urokinase.

‡Evaluation after 3 months.